Literature DB >> 1108732

[Sensitivity and resistance of pathogenic yeasts to 5-fluoropyrimidines. I.--Relation between the phenotypes of resistance to 5-fluorocytosine, the serotype of Candida albicans and the ecology of various species of Candida of human origin (author's transl)].

E Drouhet, L Mercier-Soucy, S Montplaisir.   

Abstract

The sensitivity to 5-fluorocytosine (5-FC), 5-fluorouracil (5-FU) and 5-fluorouridine (5-FUri) of 583 strains of C. albicans of human origin shows a relationship between their ecology, their serotype and their sensitivity to 5-FC. The incidence of the primary resistant strains isolated from patients with systemic candidiasis is of 4%, and 88.8% of the resistant strains belong to serotype B. In a closed community of premature infants the only resistant isolate amongst 78 strains recovered during hospitalization also belong to the B serotype and was introduced from outside. African strains of vaginal origin showed a higher incidence (21.6%) of resistance than did the european strains (4.5%) and this resistance was related to the B serotype predominant in the African environment. This raises the problem of the structure of the cell wall in connection with the active sites, the antigenic determinants and the enzymatic equipment.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1108732

Source DB:  PubMed          Journal:  Ann Microbiol (Paris)        ISSN: 0300-5410


  12 in total

Review 1.  The ins and outs of DNA fingerprinting the infectious fungi.

Authors:  D R Soll
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

Review 2.  Candida albicans strain delineation.

Authors:  W G Merz
Journal:  Clin Microbiol Rev       Date:  1990-10       Impact factor: 26.132

3.  Comparison between methods for serotyping of Candida albicans produces discrepancies in results.

Authors:  D L Brawner
Journal:  J Clin Microbiol       Date:  1991-05       Impact factor: 5.948

4.  Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States.

Authors:  R L Stiller; J E Bennett; H J Scholer; M Wall; A Polak; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

5.  Candida albicans serotype analysis by flow cytometry.

Authors:  S Mercure; S Sénéchal; P Auger; G Lemay; S Montplaisir
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

6.  Oral Candida albicans isolates from nonhospitalized normal carriers, immunocompetent hospitalized patients, and immunocompromised patients with or without acquired immunodeficiency syndrome.

Authors:  D L Brawner; J E Cutler
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

Review 7.  Drug resistance in human pathogenic fungi.

Authors:  K Iwata
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

8.  Serotype prevalence of Candida albicans from blood culture isolates.

Authors:  D L Brawner; G L Anderson; K Y Yuen
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

9.  In vitro susceptibility to 5-fluorocytosine and nystatin of common clinical yeast isolates.

Authors:  G Nobre; T Sobral; A F Ferreira
Journal:  Mycopathologia       Date:  1981-01-30       Impact factor: 2.574

10.  Killer system: a simple method for differentiating Candida albicans strains.

Authors:  L Polonelli; C Archibusacci; M Sestito; G Morace
Journal:  J Clin Microbiol       Date:  1983-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.